01—Abstract
Summary
Summary of the 10-Q filed November 12, 2024. Cited figures are marked; the original filing is the authoritative source.
BeiGene, Ltd. (ONC) reported a significant increase in total revenues for the third quarter of 2024, reaching $1,001.6 milliona, up 28.2% year-over-year, driven primarily by strong product revenue growth.
Product revenue surged by 66.9% to $993.4 millionb, largely fueled by the exceptional performance of BRUKINSA, which saw a 93.0% increase in global sales, particularly in the U.S. and Europe. Despite a substantial increase in operating expenses, the company managed to reduce its net loss. While collaboration revenue decreased significantly due to prior-year terminations, the robust growth in product sales underscores the increasing market acceptance and commercial success of BeiGene's key oncology medicines.
The company continues to invest heavily in research and development, with R&D expenses increasing by 9.5% to $496.2 millionc, reflecting its commitment to pipeline advancement. Selling, general, and administrative expenses also saw an increase of 24.5% to $455.2 million, supporting the global commercial expansion.
BeiGene ended the quarter with a healthy cash position of $2,701.9 milliond, providing ample liquidity for ongoing operations and future growth initiatives. Investors should note the ongoing legal proceedings related to patent infringement and trade secrets, which could present future risks.
02—Key points
Key Highlights
- Total revenues grew 28.2% year-over-year to $1,001.6 million in Q3 2024.
- Product revenue increased 66.9% year-over-year to $993.4 million, driven by BRUKINSA's strong performance.
- BRUKINSA global revenue reached $690.3 million, a 93.0% increase compared to the prior year.
- Research and development expenses increased by 9.5% to $496.2 million.
- Selling, general, and administrative expenses increased by 24.5% to $455.2 million.
- The company ended the quarter with $2,701.9 million in cash, cash equivalents, and restricted cash.
- BeiGene continues to expand its pipeline, with four new molecular entities entering the clinic this quarter.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q3 FY2024, BeOne Medicines Ltd. lost $0.12.
- Revenue$1.00B100.0%
- Cost of revenue−$170.5M17.0%
- Gross profit$831.1M83.0%
- Operating costs−$951.4M95.0%
- Operating income−$120.3M12.0%
- Interest, other & tax−$1.1M0.1%
- Net income−$121.3M12.1%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 12, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $1.00B$781.31M | +28.2% |
| Gross Profit | $831.14M$685.00M | +21.3% |
| R&D Expenses | $496.18M$453.26M | +9.5% |
| SG&A Expenses | $455.22M$365.71M | +24.5% |
| Operating Expenses | $951.40M$818.97M | +16.2% |
| Operating Income | -$120.27M-$133.97M | +10.2% |
| Interest Expense | $14.31M$6.63M | +115.9% |
| Net Income | -$121.35M$215.41M | −156.3% |
| EPS (Basic) | $-0.09$0.16 | −156.2% |
| EPS (Diluted) | $-0.09$0.15 | −160.0% |
| Shares Outstanding (Basic) | 1.38B1.36B | +1.2% |
| Shares Outstanding (Diluted) | 1.38B1.39B | −1.0% |
05—Questions
Frequently Asked Questions
What was BeiGene's revenue performance in Q3 2024?
BeiGene reported total revenues of $1,001.6 million for the third quarter of 2024, an increase of 28.2% compared to $781.3 million in the same period last year. Product revenue was the primary driver of this growth, rising 66.9% to $993.4 million.
How is BRUKINSA performing?
BRUKINSA continues to show exceptional growth, with global revenue reaching $690.3 million in Q3 2024, a 93.0% increase compared to the prior year. This growth is attributed to strong demand and market share gains, particularly in the U.S. and Europe.
What is the company's financial outlook and liquidity position?
BeiGene ended Q3 2024 with $2,701.9 million in cash, cash equivalents, and restricted cash, indicating a strong liquidity position to fund its ongoing operations, R&D activities, and commercial expansion. The company continues to invest in its pipeline, with R&D expenses increasing by 9.5%.
Are there any significant collaborations impacting revenue?
Collaboration revenue decreased significantly by 95.6% to $8.2 million in Q3 2024 compared to $186.0 million in the prior-year period. This decrease is primarily due to the termination of certain collaborations with Novartis in the previous year.
What are the key risks facing BeiGene based on this filing?
Key risks highlighted include ongoing patent infringement and trade secret litigation (Pharmacyclics, MSN, AbbVie), the highly regulated nature of the pharmaceutical industry, potential for delays or failures in clinical trials, competition, and dependence on successful commercialization and market acceptance of its products. The company also faces risks related to its significant operations in China and potential changes in PRC regulations.
06—Continue